On the same day, Merca East announced three major acquisition cooperation projects

May 26, MSD announced three major acquisitions and partnerships to accelerate the development of the COVID-19 vaccine and new drugs for new coronary pneumonia:Mercedon acquires Themis Bioscience, a company focused on vaccines and immunomodulation therapies for infectious diseases, including COVID-19;developed the COVID-19 vaccine in partnership with the non-profit organization IAVI, and . Mercedon and Ridge Bio developed the COVID-19 oral antiviral drug EIDD-2801.1, Mercadon's acquisition of Themis BioscienceMercedon and its focus on infectious diseases and cancer vaccines and immunomodulation therapy company Themis announced today that the two companies have reached a final agreement. Under the terms of the agreement, Mercedon will acquire all outstanding shares of Themis through a subsidiary in exchange for unanclosed cash payments. Upon completion of the transaction, Themis will become a wholly owned subsidiary of Mercedon.Themis leverages a wide range of vaccine candidates and immunomodulation therapies from its innovative Measles Vector Platform, a vector originally developed by scientists at the Pasteur Institute, the world's leading European vaccine research institution, and exclusively licensed to Themis for specific viral infection adaptations. In March, Themis, together with the Pasteur Institute and the University of Pittsburgh's Vaccine Research Center, developed a candidate vaccine targeting SARS-CoV-2 to prevent COVID-19 with funding from the Alliance for Epidemiological Preparedness and Innovation (CEPI).2, Mercedon and the non-profit organization IAVI announced a partnership to develop coVID-19 vaccine, 2020 into clinicalMercedon and IAVI, a non-profit scientific research organization dedicated to addressing pressing and unresolved global health challenges, announced a new partnership today to develop a research vaccine against SARS-CoV-2 for the prevention of COVID-19. The candidate vaccine will use recombined cystic oral inflammatory virus (rVSV) technology, which is also the technical basis for The Ebola-Zaire virus vaccine ERVEBO® (Ebola-Zaire live vaccine) in Mercedon, the first rVSV vaccine approved for use in humans. Mercadon also signed an agreement with the U.S. Biomedical Advanced Research and Development Agency (BARDA), which will provide initial funding for the work.Under the agreement, IAVI and Mercadon will jointly advance the development of SARS-CoV-2 candidate vaccines and global clinical evaluation. The vaccine candidate is in preclinical development and clinical studies are scheduled to begin later in 2020. Mercedon will be responsible for regulatory filings worldwide. If approved, the two agencies will jointly develop the vaccine and make it affordable globally.IAVI's preclinical development of the rVSV vaccine, including the SARS-CoV-2 candidate vaccine, was carried out by scientists at IAVI's Design and Development Laboratory (DDL) in Brooklyn, New York. The project is part of a long-term project led by Dr. Swati Gupta, Head of the International Alliance of Immunization's Emerging Infectious Diseases and Science Strategy, to develop rVSV vaccines for HIV and other emerging infectious diseases such as Lassa fever, Marburg and Ebola Sudan disease.3, Mercadon and Ridgeback Bio co-developed COVID-19 oral antiviral drug EIDD-2801, is in Phase 1 clinical phaseMercadon and biotech company Ridgeback Biotherapeutics announced today that the two companies have entered into a cooperation agreement to jointly develop EIDD-2801, an oral antiviral candidate that is currently in early clinical development for the treatment of COVID-19 patients. Under the terms of the agreement, Mercadon will obtain exclusive global development and commercialization rights for EIDD-2801 and related molecules through its subsidiaries.EIDD-2801 is a research oral biologic agent for powerful RNA-nucleoside analogors that inhibits the replication of a variety of RNA viruses, including SARS-CoV-2 (SARS-CoV-2, COVID-19 pathogenic factors). In animal experiments with two different coronavirus (SARS-CoV-1 and MERS), EIDD-2801 has been shown to improve lung function, reduce weight loss, and reduce the amount of virus in the lungs. THEDD-2801 was invented by Drug Innovations at Emory (DRIVE), a whon-owned non-profit biotechnology company owned by Emory University."The clinical evaluation of EIDD-2801 in COVID-19 patients has only just begun, and phase 1 studies have now shown good resistance to the compound," said Dr. Roger M. Perlmutter, President of Mercadon Research Laboratory. Since preclinical studies have shown that EIDD-2801 has strong antiviral properties for a variety of coronavirus strains, including SARS-CoV-2, we are eager to move forward with the next phase of clinical research as quickly and rescantly as possible. " (
immediate drug smell)
)